TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8051795
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem) 12 mg/kg
Study: 8051795
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem) 5 mg/kg
Study: 8051795
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem) 20-40 mg/kg
Study: 7933528
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem)
Study: 2923084
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg all‐rac‐alpha‐tocopherol and RRR‐gamma‐tocopherol
Study: 28532478
Drug: 40ml High
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40ml High Volume Image Guided Injection (HVIGI) with or without corticosteroid
Study: 28532478
Drug: 3ml local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3ml local anaesthetic sham-control injection
Study: 19732281
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (154 mEq/L)
Study: 19732281
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (0.9%) and oral N-acetylcysteine (NAC)
Study: 22905595
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with high-dose hypoallergenic 6-grass pollen preparation (SCIT)
Study: 12451325
Drug: Verapamil 180
Normalized name: verapamil 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 180 mg/day + Trandolapril 2 mg/day
Study: 12451325
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/day + Nifedipine 20 mg/day
Study: 2172178
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplement (7 g/day)
Study: 30477789
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl (TE) 250 mg TID
Study: 30477789
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl (TE) 500 mg TID
Study: 30477789
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl (TE) 500 mg TID in open-label extension (OLE)
Study: 25701700
Drug: 4.375 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.375 g/day gluten
Study: 20575400
Drug: Sanjin pills,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin pills, 3 pills 3 times a day for 7 days
Study: 19090322
Drug: APD125 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD125 10 mg
Study: 19090322
Drug: APD125 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD125 40 mg
Study: 15980934
Drug: Paracetamol 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1500 mg/day for 2 months
Study: 15324466
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) alone
Study: 1893709
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use before pregnancy
Study: 1893709
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use in early pregnancy
Study: 7049588
Drug: Proglumetacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumetacin (300 mg daily in two divided doses)
Study: 7049588
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg daily in two divided doses)
Study: 29470389
Drug: Walnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-enriched diet (43 g/day)
Study: 12436013
Drug: Psychoeducational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational Therapy (PET)
Study: 12029990
Drug: Pravastatin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (low dose, 5 mg/day)
Study: 12029990
Drug: Simvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5 to 10 mg/day for 6 years)
Study: 2693916
Drug: Oestrogen-progestogen replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen-progestogen replacement therapy for 12 months
Study: 447801
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (100 mg)
Study: 447801
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (400 mg)
Study: 31591706
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of PPD (n=29)
Study: 31591706
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections of PPD (n=29)
Study: 19487505
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (standard decompressive laminectomy with or without fusion)
Study: 15482766
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) 50 microg/24 hours
Study: 15482766
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) 75 microg/24 hours
Study: 15482766
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) 100 microg/24 hours
Study: 7815840
Drug: ATRA (all-trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (all-trans retinoic acid) treatment
Study: 2455141
Drug: Nifedipine as
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine as a capsule with high sodium intake
Study: 2455141
Drug: Nifedipine as
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine as a tablet with high sodium intake
Study: 2455141
Drug: Nifedipine with
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine with addition of a thiazide diuretic for 1 month
Study: 29866147
Drug: Actitan F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actitan F and standard oral rehydration (SOR)
Study: 29866147
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral rehydration (SOR) only
Study: 22561556
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri NCIMB 30242 capsules (n=67)
Study: 22561556
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (n=64)
Study: 20054544
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g as a 100 ml solution infused over 15 min, 1 h before anesthesia induction and then at 6-h intervals for 24 h)
Study: 20054544
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and Placebo
Study: 11004028
Drug: Clonidine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2.25 ng/mL) in awake subjects
Study: 11004028
Drug: Clonidine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2.25 ng/mL) in anesthetized subjects
Study: 1609533
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tramadol (Tramal)
Study: 1609533
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tramadol (Tramal) and 10 mg Triflupromazine (Psyquil)
Study: 1609533
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Pethidine (Alodan) and 10 mg Triflupromazine (Psyquil)
Study: 1609533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of analgesic with antiemetic
Study: 6375285
Drug: Oral pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pretreatment with verapamil for one week
Study: 6375285
Drug: 3-hour iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour iv infusion of verapamil
Study: 6375285
Drug: Oral glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glibenclamide therapy
Study: 6375285
Drug: iv infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion of verapamil
Study: 3550149
Drug: Intracavernous self-injection
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous self-injection of phentolamine and papaverine
Study: 23635012
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of dialysate sodium concentration from 138 to 135 mEq/L (Group A)
Study: 18482012
Drug: Onion extract
Normalized name: Onion Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion extract gel treatment
Study: 17058225
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg daily
Study: 12221213
Drug: Enzymatically hydrolyzed
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatically hydrolyzed isoflavone drink (1 mg total isoflavones/kg body)
Study: 12221213
Drug: Non-hydrolyzed isoflavone
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hydrolyzed isoflavone drink (1 mg total isoflavones/kg body)
Study: 7620688
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 5 mg/24 hours for 2 weeks, titrated to 10 mg/24 hours for 4 weeks if needed
Study: 7620688
Drug: Oral nitrates
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nitrates (previous treatment)
Study: 7620688
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous treatment with oral nitrates)
Study: 364393
Drug: Furosemide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (2 mg/kg intravenously)
Study: 28616772
Drug: Smoke_less (CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoke_less (CBT program: four weekly group sessions and two telephone calls over 5 weeks, n = 51)
Study: 27899150
Drug: Trials reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials reporting treatment effect estimate and/or p-value
Study: 27899150
Drug: Trials with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials with no treatment effect estimate or p-value posted
Study: 20729619
Drug: Add on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add on LAM to ADV monotherapy (Group 3)
Study: 20729619
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to ADV monotherapy (Group 1)
Study: 17039651
Drug: Zostavax vaccine
Normalized name: ZOSTAVAX VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zostavax vaccine
Study: 10476589
Drug: abciximab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (bolus and 12 hour infusion) with weight-adjusted low-dose heparin
Study: 10476589
Drug: Weight-adjusted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted heparin alone
Study: 8758450
Drug: Clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine treatment (10 days program)
Study: 1951162
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (WHO recommended dose)
Study: 6112411
Drug: Intra-articular orgotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular orgotein (4 mg/week for 6 weeks)
Study: 6112411
Drug: Intra-articular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular aspirin (4 mg/week for 6 weeks)
Study: 24134405
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous 1500 U/kg rEPO at day-1
Study: 18416955
Drug: Adjunct research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunct research project (Tromsø Mammography and Breast Cancer study)
Study: 18416955
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no adjunct research project)
Study: 1670591
Drug: Dideoxyinosine (ddl)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dideoxyinosine (ddl) administered orally in three divided doses totaling 60, 120, 180, 360, or 540 mg per square meter of body-surface area per day for 24 weeks
Study: 1670591
Drug: Dideoxyinosine (ddl)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dideoxyinosine (ddl) administered orally
Study: 26153128
Drug: atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrasentan 0.75 mg/d
Study: 26153128
Drug: atrasentan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrasentan 1.25 mg/d
Study: 24612248
Drug: Lycopene-enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-enriched virgin olive oil (300 ppm) (1.5 mL three times a day)
Study: 24612248
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 mL three times a day)
Study: 20380653
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg qd
Study: 15643227
Drug: Darifenacin controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled release (3.75 mg once daily)
Study: 15643227
Drug: Darifenacin controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled release (7.5 mg once daily)
Study: 15643227
Drug: Darifenacin controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled release (15 mg once daily)
Study: 15643227
Drug: Darifenacin immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin immediate-release (5 mg 3 times daily)
Study: 10594399
Drug: OAM b.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM b.d. (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., metronidazole 800 mg b.d.)
Study: 10594399
Drug: OAM t.d.s.
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM t.d.s. (omeprazole 40 mg o.d., amoxycillin 500 mg t.d.s., metronidazole 400 mg t.d.s.)
Study: 8214416
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg of thyrotropin-releasing hormone (TRH) IV
Study: 3116661
Drug: Fat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat (200 ml vegetable oil)
Study: 3116661
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml glucose)
Study: 22642607
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser therapy (660 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Study: 22642607
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser therapy (780 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Study: 16009884
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (44-microg three times weekly)
Study: 16009884
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (22-microg three times weekly)
Study: 1872023
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (adsorbed tetanus toxoid, 69 IIU/0.5 ml)
Study: 1872023
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (adsorbed tetanus toxoid, 212 IIU/0.5 ml)
Study: 31701429
Drug: EGCG mouthwash
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG mouthwash (starting at 440 μmol/L, three times a day, maximum tolerated dose 2200 μmol/L)
Study: 27770628
Drug: Intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Dexamethasone 30 mg perioperatively
Study: 25109511
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (tianeptine sodium 12.5 mg)
Study: 25109511
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Stablon®)
Study: 22806076
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (0.3 g/kg)
Study: 22806076
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 g/kg cornstarch maltodextrin + 0.1 g/kg sucrose)
Study: 7862853
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg at the beginning and 50 mg maintenance dose half-way through the session
Study: 2144705
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg twice daily for 3 weeks, then 20 mg twice daily for 3 weeks
Study: 2144705
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily for 3 weeks, then 100 mg once daily for 3 weeks
Study: 380608
Drug: Atropine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (2.0 mg oral, 1.0 mg i.m.)
Study: 380608
Drug: Hyoscine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (1.0 mg oral, 0.25-0.5 mg i.m.)
Study: 380608
Drug: Glycopyrronium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (0.2 mg i.m.)
Study: 31045427
Drug: Interviewer-administered condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered condition (phone or in-person)
Study: 31045427
Drug: Self-administered condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered condition (via the Assessment Center website)
Study: 25645169
Drug: iCBT (internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-delivered cognitive behavior therapy)
Study: 19458926
Drug: Eperisone 300
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone 300 mg/day
Study: 15366324
Drug: Ephedrine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.25, 0.5, and 1 mg x kg(‐1))
Study: 11336107
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g, intravenous)
Study: 2898319
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen (750 mg or 1000 mg once-a-day)
Study: 2898319
Drug: Standard marketed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard marketed naproxen (375 mg or 500 mg twice-a-day)
Study: 2898319
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen (750 mg or 1000 mg once-a-day) during open-label phase
Study: 25636011
Drug: HalfLytely© 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HalfLytely© 1 L × 2 doses and bisacodyl 5 mg delayed release tablets × 2 tablets (Protocol 1)
Study: 25636011
Drug: MiraLAX® 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiraLAX® 5 tablespoons × 2 doses and bisacodyl 5 mg tablets × 2 tablets (Protocol 2)
Study: 25636011
Drug: MoviPrep 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoviPrep 1 L × 2 doses (Protocol 3)
Study: 23486859
Drug: HPV‐16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16/18 vaccine
Study: 21244304
Drug: Various dystonia
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dystonia medications (anticholinergic agents, baclofen, clonazepam, tetrabenazine, clozapine)
Study: 7681050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Study: 27189687
Drug: Better Nights/Better
Approvals — FDA: no, EMA: no, PMDA: no
Description: Better Nights/Better Days intervention (five-session manual and weekly telephone coach support)
Study: 25590463
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) with a focus on cognitive restructuring
Study: 25590463
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) focusing on Stress Management
Study: 20096466
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pharmacotherapy and adjunctive psychosocial treatment based on a cognitive‐behavioral model)
Study: 20096466
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (standard drug treatment)
Study: 16263860
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment over 12 to 16 weeks
Study: 12411067
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt with an iodine concentration of 25 mg/kg (Group A)
Study: 12411067
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt purchased from the market + iodized oil capsules containing 400 mg iodine (Group C)
Study: 1982830
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) self‐administered R‐EPO (starting dose 92 +/‐ 35 U/kg/week) two times a week